Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| International Society for Gastrointestinal Hereditary Tumours |
RCV000075954 | SCV000106972 | pathogenic | Lynch syndrome | 2013-09-05 | reviewed by expert panel | research | Variant causes splicing aberrations (full inactivation of variant allele) |
| Ambry Genetics | RCV000215121 | SCV000276936 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-07-30 | criteria provided, single submitter | clinical testing | The p.H329P pathogenic mutation (also known as c.986A>C), located in coding exon 11 of the MLH1 gene, results from an A to C substitution at nucleotide position 986. The histidine at codon 329 is replaced by proline, an amino acid with similar properties. This alteration is identified in multiple individuals diagnosed with Lynch-related tumors that demonstrated high microsatellite instability and loss of MLH1 on immunohistochemistry (IHC) and/or whose family history met Amsterdam Criteria (Müller-Koch Y et al. Eur. J. Med. Res. 2001 Nov;6:473-82; Raevaara TE et al. Gastroenterology. 2005 Aug;129:537-49; Kansikas M et al. Hum Mutat. 2011 Jan;32:107-1; Hardt K et al. Fam Cancer. 2011 Jun;10:273-84; Ambry internal data). In an individual diagnosed with colorectal and endometrial cancer at less than 50 years of age with loss of MLH1 and PMS2 on IHC, cDNA long-range RT-PCR analysis of full-length MLH1 transcripts demonstrated that this alteration results in abnormal splicing (Morak M et al. Eur J Hum Genet. 2019 12;27:1808-1820). In addition, an unpublished observation reported that the presence of this alteration completely abrogates normal splicing of the mutant allele in cDNA-analysis (Hardt K et al. Fam Cancer. 2011 Jun;10:273-84). In two functional studies, compared to wild-type MLH1, p.H329P demonstrated similar MMR efficiency and decreased expression in one study but reduced MMR activity and retained expression in the other study (Raevaara TE et al. Gastroenterology. 2005 Aug;129:537-49; Takahashi M et al. Cancer Res. 2007 May;67:4595-604). In addition, this alteration demonstrated aberrant nuclear localization in 293T human cells (Raevaara TE et al. Gastroenterology. 2005 Aug;129:537-49). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Baylor Genetics | RCV000018614 | SCV004193014 | uncertain significance | Colorectal cancer, hereditary nonpolyposis, type 2 | 2023-04-07 | criteria provided, single submitter | clinical testing | |
| OMIM | RCV000018614 | SCV000038897 | pathogenic | Colorectal cancer, hereditary nonpolyposis, type 2 | 1997-09-01 | no assertion criteria provided | literature only |